Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 0.56 |
| ▸ | CA2 | P00918 | 16/20 | 0.56 |
| ▸ | CA4 | P22748 | 16/20 | 0.56 |
| ▸ | CA9 | Q16790 | 16/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470982 | 0.91 | CNR2 (0.55) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4478689 | 0.91 | CNR2 (0.55) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4470987 | 0.91 | CNR2 (0.55) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4472656 | 0.89 | CNR2 (0.53) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4472660 | 0.89 | CNR2 (0.53) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL13708840 | 0.89 | CNR2 (0.53) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4477036 | 0.89 | CNR2 (0.53) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4475464 | 0.89 | CNR2 (0.53) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4475466 | 0.89 | CNR2 (0.53) | CA1CA2CA4CA9CNR2 | |
| SCHEMBL4471690 | 0.88 | CA1 (0.62) | CA1CA2CA4CA9CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | CA1 3294/4885CA2 1937/4885CA4 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.